# A Study of Oral Ibogaine in Opioid Withdrawal

> **NCT05029401** · PHASE1,PHASE2 · COMPLETED · sponsor: **atai Therapeutics, Inc.** · enrollment: 116 (actual)

## Conditions studied

- Opiate Withdrawal Syndrome

## Interventions

- **DRUG:** DMX-1002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05029401
- **Lead sponsor:** atai Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-01
- **Primary completion:** 2024-01-16
- **Final completion:** 2024-01-16
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2024-08-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05029401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05029401, "A Study of Oral Ibogaine in Opioid Withdrawal". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05029401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*